Please Wait...

Survivin

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Survivin is the smallest member of the Inhibitor of Apoptosis Protein (IAP) family. The eight members of the IAPs family contain Baculoviral IAP Repeat (BIR) motifs. Initially identified in bacculovirus, BIR motif is a sequence of approximately 70 amino acids that coordinates a zinc ion (through histidine and cystine residues)(Srinivasula and Ashwell, 2008). Survivin expression was detected in different solid cancers and lymphomas (Ambrosini et al., 1997). Its role in cancer metastasis and progression as well, as its role in cell division or stems cell maintenance, have been well studied since (Altieri, 2015; Athanasoula et al., 2014). The therapeutic potential of surviving inhibition has also been investigated in clinical trials (Athanasoula et al., 2014).

Bioclinica Lab employs a manual sandwich ELISA for survivin measurement in serum.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (5 days ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (1 week ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (2 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (2 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (3 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (3 weeks ago)